UBS Group AG Acquires 88,314 Shares of Kymera Therapeutics, Inc. $KYMR

UBS Group AG lifted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 13.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 737,032 shares of the company’s stock after buying an additional 88,314 shares during the period. UBS Group AG’s holdings in Kymera Therapeutics were worth $57,348,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. US Bancorp DE raised its position in shares of Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after acquiring an additional 166 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Kymera Therapeutics by 9.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock worth $156,000 after acquiring an additional 248 shares in the last quarter. Larson Financial Group LLC raised its position in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in shares of Kymera Therapeutics by 2.2% in the 4th quarter. Harbor Capital Advisors Inc. now owns 30,573 shares of the company’s stock worth $2,379,000 after acquiring an additional 645 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Kymera Therapeutics by 5.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,631 shares of the company’s stock worth $1,216,000 after acquiring an additional 789 shares in the last quarter.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera presented new preclinical data showing KT‑579 (oral IRF5 degrader) produced activity comparable or superior to approved/clinically active therapies in IBD models — a meaningful R&D positive if confirmed in clinical studies. Article Title
• Positive Sentiment: Management will participate in multiple May investor conferences (fireside chats), increasing visibility with investors and analysts — typically supportive for sentiment and liquidity. Article Title
• Positive Sentiment: Q1 results and the accompanying presentation prompted analysts to lift estimates in some reports and coverage; positive analyst reaction to quarterly revenue and beats can support the stock. Article Title
• Neutral Sentiment: Kymera published its Q1 earnings presentation (details on pipeline progress, financials and guidance assumptions), useful for investors but not an immediate catalyst by itself. Article Title
• Neutral Sentiment: Company celebrated its 10‑year anniversary and rang the Nasdaq opening bell — PR/branding event with limited direct impact on valuation. Article Title
• Negative Sentiment: Brookline Capital Markets issued multiple model changes: they raised some near‑ and long‑term estimates (e.g., FY2026, FY2028–FY2030) but lowered Q3/Q4 2026 and FY2027 forecasts — the mixed/downgrade elements could weigh on sentiment by signaling slower expected progress or higher near‑term spend. Article Title

Kymera Therapeutics Stock Down 1.1%

Shares of NASDAQ KYMR opened at $82.71 on Wednesday. Kymera Therapeutics, Inc. has a twelve month low of $28.06 and a twelve month high of $103.00. The stock’s 50 day moving average price is $84.42 and its 200-day moving average price is $76.61. The company has a market capitalization of $6.80 billion, a PE ratio of -23.17 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same quarter in the previous year, the business earned ($0.82) EPS. The company’s revenue was up 55.5% compared to the same quarter last year. As a group, research analysts expect that Kymera Therapeutics, Inc. will post -3.35 EPS for the current fiscal year.

Analysts Set New Price Targets

KYMR has been the subject of several research reports. Jefferies Financial Group initiated coverage on Kymera Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $110.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Barclays raised their target price on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research note on Tuesday, January 27th. Finally, Citigroup raised their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.10.

Insider Transactions at Kymera Therapeutics

In related news, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total value of $2,707,800.00. Following the transaction, the chief executive officer directly owned 666,195 shares of the company’s stock, valued at approximately $60,130,760.70. The trade was a 4.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jeremy G. Chadwick sold 91,250 shares of the business’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $77.41, for a total transaction of $7,063,662.50. Following the completion of the transaction, the chief operating officer directly owned 61,202 shares in the company, valued at $4,737,646.82. This trade represents a 59.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 380,734 shares of company stock worth $32,193,902. 16.01% of the stock is owned by insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.